Average Co-Inventor Count = 2.18
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Ionis Pharmaceuticals, Inc. (41 from 270 patents)
2. Cold Spring Harbor Laboratory (7 from 189 patents)
3. Biogen Ma Inc. (6 from 247 patents)
4. Rosalind Franklin University of Medicine and Science (3 from 48 patents)
5. University of California (2 from 15,331 patents)
6. University of Texas System (2 from 5,401 patents)
7. The Johns Hopkins University (2 from 3,663 patents)
8. Washington University (2 from 1,557 patents)
9. Isis Pharmaceuticals, Inc. (2 from 1,035 patents)
10. Academisch Ziekenhuis Leiden (2 from 47 patents)
11. University of Michigan (1 from 3,325 patents)
12. Baylor College of Medicine (1 from 596 patents)
13. Ludwig Institute for Cancer Research Limited (1 from 525 patents)
14. Fred Hutchinson Cancer Center (1 from 286 patents)
15. Ludwig Institute for Cancer (1 from 2 patents)
49 patents:
1. 12275940 - Conjugated antisense compounds and their use
2. 12188020 - Methods for reducing Ataxin-2 expression
3. 12013403 - Compositions and methods for detection of SMN protein in a subject and treatment of a subject
4. 11926825 - Compounds and methods for reducing ATXN2 expression
5. 11833221 - Oligomeric compounds for reducing DMPK expression
6. 11786546 - Compounds and methods for modulating GFAP
7. 11781135 - Methods for treating Alzheimer's disease
8. 11732260 - Compounds and methods for the modulation of amyloid-β precursor protein
9. 11725208 - Conjugated antisense compounds and their use
10. 11661601 - Methods for modulating FMR1 expression
11. 11535848 - Compositions and methods for modulation of SMN2 splicing in a subject
12. 11459564 - Modulation of frataxin expression
13. 11339393 - Compositions for modulating C9ORF72 expression
14. 11299737 - Compounds and methods for modulating SMN2
15. 11293025 - Compositions and methods for modulating Ataxin 3 expression